European Medicines Agency: mRNA COVID-19 vaccine is not associated with autoimmune hepatitis
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
European Medicines Agency: mRNA COVID-19 vaccine is not associated with autoimmune hepatitis
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
European Medicines Agency: mRNA COVID-19 vaccine is not associated with autoimmune hepatitis.
Recently, a study on “COVID-19 vaccine may cause a rare T cell-mediated autoimmune hepatitis” published in the Journal of Hepatology, a journal in the field of liver disease concerns about adverse reactions.
The paper, which was finalized on March 31, 2022, refers to a case report in Germany of a 52-year-old man who developed a bimodal flare of acute hepatitis after 2 doses of mRNA vaccine.
In this regard, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) announced on April 8 that there is currently no evidence to support a causal relationship between the mRNA COVID-19 vaccine and autoimmune hepatitis (AIH), and no update is currently required. Product information for vaccines.
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) discussed the case at its April 2-7 meeting and subsequently released its latest minutes.
Autoimmune hepatitis (AIH) is a very rare chronic progressive liver inflammatory disease mediated by an autoimmune response, according to the PRAC meeting minutes. The PRAC came to this conclusion after reviewing literature data, AIH cases reported to the EudraVigilance database and further data provided by marketing authorisation holders.
The European Medicines Agency (EMA) said it will continue to closely monitor any new situation reports and take appropriate measures if necessary.
(source:internet, reference only)
Disclaimer of medicaltrend.org
